The Floodlight MS app, used to track disease progression in people with multiple sclerosis, has been deemed cost-effective in ...

Since being diagnosed with multiple sclerosis (MS) in 2018, Blair has emerged as a fierce advocate for those living with ...

Multiple sclerosis (MS) is a disease that affects the brain and spinal cord. It happens when the body’s immune system ...

Getting at least 30 minutes of daily summer sun in the first year of life may mean a lower relapse risk for children who are diagnosed with multiple sclerosis (MS) later, according to a study ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

Sales of the company's Alzheimer's disease treatment leqembi came to about $87 million, ahead of the $67 million FactSet consensus. But sales of the core multiple-sclerosis portfolio ... as further ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...